Umbralisib NEW
| Price | $41 | $59 | $97 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-15 |
Product Details
| Product Name: Umbralisib | CAS No.: 1532533-67-7 |
| Purity: 99.56% | Supply Ability: 10g |
| Release date: 2025/07/15 |
Product Introduction
Bioactivity
| Name | Umbralisib |
| Description | Umbralisib (TGR 1202) is a PI3Kδ inhibitor. |
| In vitro | Umbralisib and carfilzomib synergistically kill blood cancer cells through disrupting the 4E-BP1-eIF4F-c-Myc axis. Umbralisib and carfilzomib in combination synergistically and selectively silence the c-Myc and E2F transcription programs. Umbralisib (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells. |
| In vivo | In a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line, TGR-1202 (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 91 mg/mL (159.22 mM), Sonication is recommended. |
| Keywords | Umbralisib | RP-5264 | RP 5264 | PI3Kδ | PI3K | Phosphoinositide 3-kinase | orally active | lymphoma | lymphocytic leukemia | Inhibitor | inhibit | haematological malignancies | CLL T cells | Casein Kinase | cancer |
| Inhibitors Related | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | 3-Methyladenine | Duvelisib (R enantiomer) hydrochloride | Isoprenaline hydrochloride | Quercetin | Inavolisib | Quercetin Dihydrate | Apilimod | Idelalisib |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Target-Focused Phenotypic Screening Library | Approved Drug Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $197.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-19 | |
| $53.00/2mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY